Bio Innovation Conference | Claire Leurent, Ph.D., MBA
Presented by Maryland Life Sciences, a division of the Maryland Tech Council, the Bio Innovation Conference is driving the future of life sciences in Maryland. This conference provides a forum for professionals from industry, academia and government to discuss trends and insight into Maryland’s burgeoning life sciences industry and topics related to funding, structuring, commercialization and government relations.
Maryland, life sciences, biotechnology, Maryland Tech Council, bio, innovation, conference, Maryland Life Sciences, Bio Innovation Conference, vaccines, gene therapy, networking, Washington DC, DMV, Biohealth, biohealth capital region, sciences, entrepreneurship, entrepreneur, startup, Maryland Life Sciences Bio Innovation Conference, Maryland Tech Council Conference, annual conference
19824
page-template-default,page,page-id-19824,page-child,parent-pageid-16863,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive
 

Claire Leurent, Ph.D., MBA

Claire Leurent, Ph.D., MBA

Principal, Venture Investments, Johnson & Johnson Innovation

Claire is Principal of Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in Boston MA.  Claire focuses on pharmaceutical investments in areas of strategic interest to Johnson & Johnson.

Prior to joining JJDC, Claire was Investment Director, then Managing Director, at Samsung Ventures with a focus on Life Science, Health Economics and Connected Health sectors.  Prior to Samsung Ventures, she spent 14 years in the pharmaceutical industry in R&D. At Pfizer, she led teams in design and implementation of clinical plans from First in Human to Proof of Concept studies with end-to-end accountability for various development programs ranging from small molecules and biologics to digital technologies.  Prior to Pfizer, Claire supported large global multicentric phase 3 pre/registration studies and launch activities at Wyeth Pharmaceuticals in Neuroscience and Women Health.  Prior to Wyeth, she was Project Manager at Forenap, a neuroscience CRO, where she advanced a portfolio of clinical protocols for diverse global pharma clients. In this position, she acquired first-hand operational experience in clinical trials and oversaw First in Human studies at the Phase 1 center.

Claire earned her PhD in molecular and cellular biology at the Institute of Genetics, Molecular and Cellular Biology (IGBMC) of Strasbourg, France. She also earned a certificate in Pharmacology from La Pitié-Salpêtrière (Paris VI), and the FIEC certificate in Clinical Trial from Louis Pasteur University (ULP, Strasbourg). She earned her MBA at MIT Sloan.